المؤلفون: Kandzari DE; Department of Interventional Cardiology, Piedmont Heart Institute, Atlanta, GA (D.E.K.)., Kirtane AJ; Department of Interventional Cardiology, Columbia University Irving Medical Center/New York-Presbyterian Hospital (A.J.K., T.N.).; Cardiovascular Research Foundation, New York, NY (A.J.K., G.W.S.)., Windecker S; Department of Cardiovascular Diseases, University Hospital, University of Bern, Switzerland (S.W.)., Latib A; Department of Interventional Cardiology, Montefiore Medical Center, New York, NY (A.L.)., Kedhi E; Department of Cardiology, Isala Zwolle, the Netherlands (E.K.)., Mehran R; Department of Cardiology, School of Medicine at Mount Sinai, New York, NY (R.M., G.W.S.)., Price MJ; Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA (M.J.P.)., Abizaid A; Department of Interventional Cardiology, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil (A.A.)., Simon DI; Department of Interventional Cardiology, University Hospitals Cleveland Medical Center, OH (D.I.S.)., Worthley SG; Department of Cardiology, GenesisCare, Alexandria, Australia (S.G.W.)., Zaman A; Department of Cardiology, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom (A.Z.)., Choi JW; Department of Interventional Cardiology, Baylor Scott and White Heart and Vascular Hospital, Dallas, TX (J.W.C.)., Caputo R; Department of Interventional Cardiology, St. Joseph's Hospital, Syracuse, NY (R.C.)., Kanitkar M; Department of Interventional Cardiology, Huntsville Hospital, AL (M.K.)., McLaurin B; Department of Interventional Cardiology, Anmed Health Medical Center, Anderson, SC (B.M.)., Potluri S; Department of Interventional Cardiology, The Heart Hospital Baylor Plano, TX (S.P.)., Smith T; Department of Interventional Cardiology, The Christ Hospital, Cincinnati, OH (T.S.)., Spriggs D; Department of Interventional Cardiology, Morton Plant Hospital, Clearwater, FL (D.S.)., Tolleson T; Department of Cardiology, UT Health East Texas, Tyler (T.T.)., Nazif T; Department of Interventional Cardiology, Columbia University Irving Medical Center/New York-Presbyterian Hospital (A.J.K., T.N.)., Parke M; Coronary and Structural Heart Division, Medtronic, Santa Rosa, CA (M.P., L.C.L., T.-H.L.)., Lee LC; Coronary and Structural Heart Division, Medtronic, Santa Rosa, CA (M.P., L.C.L., T.-H.L.)., Lung TH; Coronary and Structural Heart Division, Medtronic, Santa Rosa, CA (M.P., L.C.L., T.-H.L.)., Stone GW; Cardiovascular Research Foundation, New York, NY (A.J.K., G.W.S.).; Department of Cardiology, School of Medicine at Mount Sinai, New York, NY (R.M., G.W.S.).

مؤلفون مشاركون: Onyx ONE US/Japan Investigators

المصدر: Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2020 Nov; Vol. 13 (11), pp. e009565. Date of Electronic Publication: 2020 Nov 10.

نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101499602 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-7632 (Electronic) Linking ISSN: 19417640 NLM ISO Abbreviation: Circ Cardiovasc Interv Subsets: MEDLINE

مواضيع طبية MeSH: Drug-Eluting Stents* , Dual Anti-Platelet Therapy*/adverse effects, Cardiovascular Agents/*administration & dosage , Coronary Artery Disease/*therapy , Percutaneous Coronary Intervention/*instrumentation , Platelet Aggregation Inhibitors/*administration & dosage , Sirolimus/*analogs & derivatives, Aged ; Aged, 80 and over ; Coronary Artery Disease/diagnostic imaging ; Coronary Artery Disease/mortality ; Drug Administration Schedule ; Female ; Hemorrhage/chemically induced ; Humans ; Japan ; Male ; Middle Aged ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Prospective Studies ; Prosthesis Design ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Sirolimus/administration & dosage ; Time Factors ; Treatment Outcome ; United States